Will Walls Come Tumbling Down?

The Public Library of Science, whose editorial board reads like a Who's Who of the biology community,1 is slated to start publishing later on this year. PLoS will practice what it has preached: open-access publication, joining BioMed Central (a sister company of The Scientist), which has been publishing open-access journals for the last two years. If successful, this approach will trigger a seismic change in academic publishing. What is open-access publishing all about and who will it benefit

Written byRichard Gallagher
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The Public Library of Science, whose editorial board reads like a Who's Who of the biology community,1 is slated to start publishing later on this year. PLoS will practice what it has preached: open-access publication, joining BioMed Central (a sister company of The Scientist), which has been publishing open-access journals for the last two years. If successful, this approach will trigger a seismic change in academic publishing.

What is open-access publishing all about and who will it benefit? It is about providing free, unlimited access to research papers to anyone with online capabilities. It is also about removing restrictions on redistribution or reuse of published material.

The most obvious beneficiaries are scientists with limited funds, such as those working in poorer countries, smaller institutes, and unfashionable fields. But even in large, well-funded centers library budgets are feeling the pinch and can't stretch to include every journal desired, so all scientists ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies